Clinical Trial Update: Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)

View source ↗

Summary

A clinical trial update investigating whether prodigiosin or pioglitazone can modulate the tumor immune microenvironment and its crosstalk with immune checkpoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)
• Prodigiosin (prodigiosin)

Snippet

Sponsor: Ain Shams University | Conditions: Lung Cancer, NSCLC | Status: NOT_YET_RECRUITING